IP Verse

Method Of Identifying Treatment Responsive Non-Small Cell Lung Cancer Using Anaplastic Lymphoma Kinase (Alk) As A Marker - EP2898329

The patent EP2898329 was granted to Ventana Medical Systems on May 17, 2017. The application was originally filed on Mar 14, 2013 under application number EP13712120A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2898329

VENTANA MEDICAL SYSTEMS
Application Number
EP13712120A
Filing Date
Mar 14, 2013
Status
Opposition Rejected
Oct 11, 2019
Publication Date
May 17, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEFeb 19, 2018- -

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0120694
DESCRIPTIONEP0125023
DESCRIPTIONEP0256654
DESCRIPTIONUS2012171668
DESCRIPTIONUS4444487
DESCRIPTIONUS4745055
DESCRIPTIONUS7230098
DESCRIPTIONUS7825137
DESCRIPTIONUS7858643
DESCRIPTIONUS8217057
DESCRIPTIONWO8803565
INTERNATIONAL-SEARCH-REPORTWO2012070730
OPPOSITIONWO2012070730
OTHERWO2012070730

Non-Patent Literature (NPL) Citations (36) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ALK 2 in 1 Control Slides, VENTANA MEDICAL SYSTEMS, INC.
DESCRIPTION- BEASLEY ET AL., SEMIN. ROENTGENOL., (2004), vol. 40, pages 90 - 97
DESCRIPTION- FAOULKNER ET AL., NATURE, (1982), vol. 298, page 286
DESCRIPTION- IWAHARA ET AL., ONCOGENE, (1997), vol. 14, pages 439 - 449
DESCRIPTION- KWAK ET AL., N. ENGL. J. MED., (2010), vol. 363, pages 1693 - 1703
DESCRIPTION- MINO-KENUDSON, CLIN. CANCER RES., (2010), vol. 16, pages 1561 - 1571
DESCRIPTION- MORRISON ET AL., ANN REV. LMMUNOL., (1984), vol. 2, page 239
DESCRIPTION- MORRISON,./., IMMUNOL., (1979), vol. 123, page 793
DESCRIPTION- SHAW ET AL., LANCET ONCOL., (2011), vol. 12, pages 1004 - 1012
DESCRIPTION- SODA, NALURE, (2007), vol. 448, pages 561 - 566
DESCRIPTION- YI ET AL., J. 77IORAC. OTICOL., (2011), vol. 6, pages 459 - 465
EXAMINATION- Ventana ALKF3 CDx Assay data sheet
INTERNATIONAL-SEARCH-REPORT- ERIK THUNNISSEN ET AL, "EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations", VIRCHOWS ARCHIV, SPRINGER, BERLIN, DE, (20120724), vol. 461, no. 3, doi:10.1007/S00428-012-1281-4, ISSN 1432-2307, pages 245 - 257, XP035106191 [X] 1-19 * the whole document * * page 245 - page 249 * * table 2 * [I] 20-23
INTERNATIONAL-SEARCH-REPORT- YI E S ET AL, "Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH", JOURNAL OF THORACIC ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, PA, US, (20110301), vol. 6, no. 3, doi:10.1097/JTO.0B013E318209EDB9, ISSN 1556-0864, pages 459 - 465, XP002680356 [X] 1-19 * the whole document * * abstract * * page 464 * [I] 20-23
INTERNATIONAL-SEARCH-REPORT- NIR PELED ET AL, "Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non-Small-Cell Lung Cancer", JOURNAL OF THORACIC ONCOLOGY, (20120901), vol. 7, no. 9, doi:10.1097/JTO.0b013e3182614ab5, ISSN 1556-0864, pages e14 - e16, XP055063267 [X] 1-19 * the whole document * * page 14, column 2, paragraph 4 * [I] 20-23
OPPOSITION- ADVANCE
OPPOSITION- "Guidance for ALK Gene Testing in Lung Cancer Patients", Japan Lung Cancer Society, (20110000), XP055468672
OPPOSITION- K. TAKEUCHI, "ALK-positive lung cancer - Pathology diagnosis using formalin-fixed paraffin-embedded materials", Igaku no Ayumi (The Step of Medicine), (20110000), vol. 237, no. 12, pages 1105 - 1111, XP055317100
OPPOSITION- M. MINO-KENUDSON et al., "A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry", Clinical Cancer Research, (20100000), vol. 16, pages 1561 - 1571, XP055468640
OPPOSITION- "OptiView Amplification Kit", Ventana Medical Systems, (20120000), XP055468682
OPPOSITION- "OptiView DAB IHC Detection Kit", Ventana, (20110000), pages 1 - 4, XP055317076
OPPOSITION- "OptiView Detection Chemistry", Ventana medical Systems, (20110000), XP055317068
OPPOSITION- "Ventana ALK (D5F3) CDx Assay Interpretation Guide for Non-Small Cell Lung Carcinoma (NSCLC)", Ventana Medical Systems, (20170000), XP055468677
OPPOSITION- "Ventana to collaborate with Pfizer and CST on companion diagnostic to identify lung cancer patients with ALK gene rearrangements", Media Release, (20120110), pages 1 - 3, XP055317062
OPPOSITION- E. TUNNISSEN et al., "EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations", Virchows Arch., (20120000), vol. 461, no. 3, pages 245 - 257, XP035106191
OPPOSITION- E.L. KWAK et al., "Anaplastic Lymphoma Kinase Inhibition in Non-Small- Cell Lung Cancer", New England Journal of Medicine, (20100000), vol. 363, no. 18, pages 1693 - 1703, XP055081495
OPPOSITION- E.S. YI et al., "Correlation of IHC and FISH for ALK Gene Rearrangement in Non-Small Cell Lung Carcinoma", Journal of Thoracic Oncology, (20110000), vol. 6, no. 3, pages 459 - 465, XP002680356
OPPOSITION- H. KIM et al., "Detection of ALK gene rearrangement in non-small cell lung cancer: A comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression", Journal of Thoracic Oncology, (20110000), vol. 6, no. 8, pages 1359 - 1366, XP008162210
OPPOSITION- K. TAKEUCHI et al., "KIF5B-ALK, A Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer", Clinical Cancer Research, (20090000), vol. 15, no. 9, pages 3143 - 3149, XP055069999
OTHER- KENGO TAKEUCHI, "ALK-posltlve lung cancer-Pathology diagnosis using formalin-fixed paraffin-embedded materials", Journal of Clinical and Experimental Medicine (IGAKU NO AYUMI), (20110618), vol. 237, no. 12, pages 1104 - 1111, XP055317100
OTHER- "OptiView DAB IHC Detection Kit", Ventana, (20110623), pages 1 - 4, XP055317076
OTHER- "OptiView Detection Chemistry", Ventana Brochure, (20110000), URL: http://www.ventana.com/documents/OptiView_F&B _Brochure.pdf, XP055317068
OTHER- "Ventana to collaborate with Pfizer and CST on companiondiagnostic to identify lung cancer patients with ALK generearrangements", Ventana Media Release, (20120110), pages 1 - 3, URL: http://www.ventana.com/documents/media/Ventana_CST_Pfizer_Release.pdf, XP055317062
OTHER- ERIK THUNNISSEN et al, "EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations", Vichows Arch, (20120724), vol. 461, no. 3, pages 245 - 257, XP035106191
OTHER- YI E.S., "Correlation of IHC and FISH for ALK Gene Rearrangement in Non-Small Cell Lung Carcinoma. IHC Score Algorithm for FISH", Journal of Thoracic Oncology, (20110311), vol. 6, no. 3, pages 459 - 465, XP002680356
OTHER- NIR PELED, "Next Generation Sequencing Identifies and lmmunohistochemistry Confirms a Novel Crizotinib Sensitive ALK Rearrangement in a Patient with Metastatic Non-small Cell Lung Cancer", J Thorac Oncol., (20120901), vol. 7, no. 9, pages e14 - e16, XP055063267

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents